Detalhe da pesquisa
1.
Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer.
Curr Oncol Rep
; 25(7): 689-698, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37004700
2.
Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer.
Oncologist
; 23(11): 1300-1309, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30139837
3.
Comprehensive Analysis Identifies Variability in PI3K Pathway Alterations in Triple-Negative Breast Cancer Subtypes.
JCO Precis Oncol
; 8: e2300124, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38484209
4.
Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP.
J Clin Oncol
; 41(27): 4433-4442, 2023 09 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37433103
5.
Optimizing (neo)adjuvant treatment of HER2-positive breast cancer.
Ther Adv Med Oncol
; 10: 1758835918775697, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30034547
6.
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer.
JCO Precis Oncol
; 20182018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30035249
7.
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab.
JAMA Oncol
; 3(4): 509-515, 2017 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27893038
8.
Clinical outcomes based on multigene profiling in metastatic breast cancer patients.
Oncotarget
; 7(47): 76362-76373, 2016 Nov 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-27806348